Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
AXSM Axsome Therapeutics, Inc. daily Stock Chart
AXSM [NASD]
Axsome Therapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.13 Insider Own0.10% Shs Outstand31.22M Perf Week6.13%
Market Cap108.02M Forward P/E- EPS next Y-0.61 Insider Trans- Shs Float20.75M Perf Month-11.73%
Income-28.80M PEG- EPS next Q-0.30 Inst Own11.90% Short Float4.24% Perf Quarter4.85%
Sales- P/S- EPS this Y10.50% Inst Trans-13.30% Short Ratio3.06 Perf Half Y-2.54%
Book/sh0.03 P/B115.33 EPS next Y- ROA-113.70% Target Price19.00 Perf Year-28.29%
Cash/sh0.49 P/C7.11 EPS next 5Y- ROE-310.90% 52W Range2.05 - 5.95 Perf YTD-38.21%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.85% Beta-
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin- 52W Low68.78% ATR0.31
Employees27 Current Ratio1.50 Sales Q/Q- Oper. Margin- RSI (14)56.30 Volatility12.44% 10.68%
OptionableYes Debt/Eq11.00 EPS Q/Q-15.60% Profit Margin- Rel Volume1.44 Prev Close3.39
ShortableYes LT Debt/Eq6.29 EarningsNov 09 BMO Payout- Avg Volume287.64K Price3.46
Recom1.50 SMA209.56% SMA50-0.83% SMA20011.64% Volume407,779 Change2.06%
Oct-03-16Resumed Brean Capital Buy
Dec-15-15Initiated Cantor Fitzgerald Buy
Dec-14-15Initiated Ladenburg Thalmann Buy
Dec-11-18 06:55AM  Today's Research Reports on Trending Tickers: Axsome Therapeutics and Avid Bioservices ACCESSWIRE
Dec-10-18 08:25AM  UPDATE: Axsome Therapeutics shares soar 24% premarket on positive trial of Alzheimer's therapy MarketWatch +14.92%
07:00AM  Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimers Disease Agitation GlobeNewswire
Nov-27-18 07:00AM  Axsome Therapeutics Expands Loan Agreement with Silicon Valley Bank Providing Additional Growth Capital Related to AXS-12 Product Candidate GlobeNewswire
Nov-21-18 08:50AM  Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-19-18 07:00AM  Axsome Therapeutics to Participate in 2018 Global Mizuho Investor Conference GlobeNewswire +9.22%
Nov-14-18 07:00AM  Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder GlobeNewswire
Nov-09-18 07:42AM  Axsome: 3Q Earnings Snapshot Associated Press
07:00AM  Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Nov-01-18 07:00AM  Axsome Therapeutics to Report Third Quarter 2018 Financial Results on November 9, 2018 GlobeNewswire
Oct-18-18 07:00AM  Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimers Disease Agitation GlobeNewswire
Oct-17-18 07:00AM  Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy GlobeNewswire +11.36%
Oct-16-18 07:05AM  Axsome Therapeutics to Host Call Today with Key Opinion Leader Focusing on AXS-12 and Unmet Needs in Narcolepsy GlobeNewswire +5.07%
07:00AM  Axsome Therapeutics Announces AXS-12 for the Treatment of Narcolepsy GlobeNewswire
Oct-12-18 07:00AM  Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Oct-11-18 07:00AM  Axsome Therapeutics to Focus on Growing Core CNS Portfolio; Establishes Axsome Pain and Primary Care Business Unit to Enhance Value of Non-CNS Assets GlobeNewswire
Sep-28-18 07:00AM  Axsome Therapeutics Announces $8.9 Million Registered Direct Offering GlobeNewswire
Sep-26-18 03:57PM  What Does Axsome Therapeutics Incs (NASDAQ:AXSM) Ownership Structure Look Like? Simply Wall St.
Sep-24-18 07:00AM  Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-19-18 07:00AM  Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Alzheimers Disease Agitation GlobeNewswire
Aug-28-18 07:00AM  Axsome Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire +18.81%
Aug-08-18 07:40AM  Axsome: 2Q Earnings Snapshot Associated Press
07:00AM  Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
06:00AM  Axsome Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 07:00AM  Axsome Therapeutics to Report Second Quarter 2018 Financial Results on August 8, 2018 GlobeNewswire
Jul-17-18 07:00AM  Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimers Association International Conference GlobeNewswire
Jun-05-18 07:00AM  Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder GlobeNewswire +5.88%
May-29-18 07:00AM  Axsome Therapeutics to Present Data on AXS-05 at the 2018 American Society of Clinical Psychopharmacology Annual Meeting GlobeNewswire
May-22-18 07:00AM  Axsome Therapeutics to Present at the 2018 BIO International Convention GlobeNewswire
May-08-18 10:43AM  Is Axsome Therapeutics Incs (NASDAQ:AXSM) CEO Incentives Align With Yours? Simply Wall St.
09:24AM  Axsome: 1Q Earnings Snapshot Associated Press
07:00AM  Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
06:15AM  Axsome Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-03-18 07:00AM  Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric Association GlobeNewswire
May-01-18 07:00AM  Axsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018 GlobeNewswire
Apr-26-18 07:00AM  Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression GlobeNewswire +13.21%
Apr-25-18 07:30AM  Wired News Axsome Therapeutics Initiated Phase-2 Clinical Trial of AXS-05 in Smoking Cessation ACCESSWIRE
Apr-24-18 07:00AM  Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimers Disease Agitation, and Nicotine Dependence GlobeNewswire
Apr-23-18 07:00AM  Axsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking Cessation GlobeNewswire
Apr-19-18 08:18PM  Should You Be Concerned About Axsome Therapeutics Incs (NASDAQ:AXSM) Investors? Simply Wall St.
07:00AM  Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer GlobeNewswire
Apr-11-18 07:00AM  Axsome Therapeutics to Participate in the Leerink Partners 2018 CNS Day GlobeNewswire
Mar-27-18 07:00AM  Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimers Disease Agitation, and Nicotine Dependence GlobeNewswire
Mar-26-18 07:00AM  Axsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire
Mar-19-18 07:00AM  Axsome Therapeutics to Present at 17th Annual Needham Healthcare Conference GlobeNewswire
Mar-12-18 07:00AM  Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics GlobeNewswire
Mar-07-18 07:20AM  Axsome reports 4Q loss Associated Press
07:00AM  Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update GlobeNewswire
06:00AM  Axsome Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-28-18 07:00AM  Axsome Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018 GlobeNewswire
Feb-26-18 08:20AM  Benzinga Pro's 4 Stocks To Watch Today Benzinga
07:00AM  Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan GlobeNewswire
Feb-14-18 07:29PM  Is Axsome Therapeutics Incs (NASDAQ:AXSM) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Feb-05-18 07:00AM  Axsome Therapeutics to Present at 2018 BIO CEO & Investor Conference GlobeNewswire
Jan-10-18 09:17AM  Heres Whats Moving Axsome Therapeutics and Pain Therapeutics Market Exclusive
08:00AM  Todays Research Reports on Stocks to Watch: Immunomedics, Inc. and Axsome Therapeutics ACCESSWIRE
Jan-09-18 07:00AM  Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial GlobeNewswire -36.04%
Dec-19-17 07:00AM  Axsome Therapeutics to Present at Biotech Showcase 2018 GlobeNewswire
Dec-14-17 07:00AM  Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation GlobeNewswire
Dec-06-17 07:00AM  Axsome Therapeutics Announces Closing of $9.5 Million Registered Direct Offering GlobeNewswire
Dec-01-17 07:00AM  Axsome Therapeutics Announces $9.5 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -6.64%
Nov-28-17 07:00AM  Axsome Therapeutics Announces AXS-07 for the Treatment of Migraine GlobeNewswire
Nov-08-17 09:59AM  Axsome reports 3Q loss Associated Press -5.15%
07:00AM  Axsome Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Sep-18-17 07:00AM  Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-07-17 07:00AM  Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017 GlobeNewswire
Aug-09-17 10:25PM  Axsome reports 2Q loss Associated Press
07:00AM  Axsome Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Jul-25-17 07:00AM  Axsome Therapeutics Announces AXS-06 (MoSEIC Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial GlobeNewswire
Jul-17-17 07:00AM  Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimers Disease Agitation GlobeNewswire
Jul-06-17 07:00AM  Axsome Therapeutics Appoints John Golubieski as Chief Financial Officer GlobeNewswire
Jun-22-17 04:40AM  Will Axsome Therapeutics (AXSM) Continue to Surge Higher? Zacks
Jun-19-17 07:00AM  Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors GlobeNewswire +12.20%
May-09-17 09:55AM  Axsome reports 1Q loss Associated Press
08:15AM  Blog Coverage: Axsome Received Fast Track Designation for its Treatment of Agitation in Patients with Alzheimer's Disease Accesswire
07:00AM  Axsome Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
May-08-17 07:00AM  Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimers Disease Agitation GlobeNewswire +7.69%
Mar-31-17 04:32PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -7.14%
Mar-30-17 04:32PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-29-17 07:00AM  Axsome Therapeutics Announces Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Mar-23-17 07:00AM  Axsome Therapeutics to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-21-17 05:30PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -18.18%
09:20AM  Axsome Therapeutics Announces Pricing of Its Public Offering of Common Stock GlobeNewswire
Mar-20-17 04:06PM  Axsome Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-14-17 07:02AM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-11-17 01:04PM  AXSOME THERAPEUTICS, INC. Financials
Mar-07-17 05:56PM  Axsome reports 4Q loss Associated Press -9.18%
05:17PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:56PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:35PM  Axsome Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update GlobeNewswire
Feb-27-17 07:00AM  Axsome Therapeutics to Present at the 29th Annual ROTH Conference GlobeNewswire +5.81%
Feb-14-17 05:24PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant Depression GlobeNewswire
Feb-13-17 07:00AM  Axsome Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference GlobeNewswire
Feb-10-17 07:01AM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-07-17 07:00AM  Axsome Therapeutics to Present at the 2017 BIO CEO & Investor Conference GlobeNewswire
Jan-12-17 05:30PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jan-04-17 05:14PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Axsome Therapeutics to Present at Biotech Showcase 2017 GlobeNewswire
Jan-03-17 07:00AM  Axsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimers Disease Agitation GlobeNewswire
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical trial in knee osteoarthritis associated with bone marrow lesions pursuant to a special protocol assessment and in chronic low back pain associated with Modic changes. AXS-07 is in Phase I clinical trial for the acute treatment of migraine. AXS-06 is also in Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastric ulcers. AXS-09 is a novel, oral medicine combination of esbupropion and dextromethorphan, which is in Phase I clinical trial. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. It has operations in the United States and Australia. The company was founded in 2012 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pizzie NickChief Financial OfficerJun 19Buy3.1031,00096,08031,000Jun 20 05:00 PM
open in yahoo | open in reuters | open in google